利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

203 条记录 (耗时 0.034 秒)

    PROTEINS USED FOR THE DIAGNOSIS OF LYME BORRELIOSIS
    14.
    发明申请
    PROTEINS USED FOR THE DIAGNOSIS OF LYME BORRELIOSIS 有权
    用于诊断LYME BORRELIOSIS的蛋白质

    公开(公告)号：US20120156694A1

    公开(公告)日：2012-06-21

    申请号：US13388168

    申请日：2010-08-27

    申请人： Lionel Levet ,  Odile Mejan-Letourneur

    发明人： Lionel Levet ,  Odile Mejan-Letourneur

    IPC分类号： G01N33/53 ,  C07K14/235 ,  C07H21/04 ,  C12N15/63

    CPC分类号： C07K14/20 ,  A61K39/00 ,  C07K14/195 ,  G01N33/56911 ,  G01N2333/20 ,  G01N2469/20 ,  Y02A50/401 ,  Y02A50/57

    摘要： Chimera proteins including: (i) at least one sequence of a VlsE protein of a Borrelia species selected from B. garinii, B. burgdorferi sensu stricto and B. afzelii, and (ii) at least one sequence including sequences of the IR6 domain of B. burgdorferi sensu stricto, B. afzelii and B. garinii. Also, a method and a kit for the in vitro diagnosis of Lyme borreliosis using said proteins.

    摘要翻译： 嵌合体蛋白质包括：（i）至少一种选自加利福尼亚芽孢杆菌（B. garinii），布氏疏螺旋体（B.burgdorferi sensu stricto）和非洲弧菌属（B. afzelii）的疏螺旋体的VlsE蛋白的序列，以及（ii）至少一个包括IR6结构域的序列的序列 Burgdorferi sensu stricto，B. afzelii和B. garinii。 此外，使用所述蛋白质用于体外诊断莱姆芽孢杆菌病的方法和试剂盒。

    Defective entities and uses therefor
    16.
    发明申请
    Defective entities and uses therefor 审中-公开
    不良实体及其用途

    公开(公告)号：US20050238657A1

    公开(公告)日：2005-10-27

    申请号：US10500250

    申请日：2002-12-30

    申请人： Rene Cornford-Nairn ,  Grant Daggard ,  Trilochan Mukkur ,  Tony Rossetti

    发明人： Rene Cornford-Nairn ,  Grant Daggard ,  Trilochan Mukkur ,  Tony Rossetti

    IPC分类号： A61K38/00 ,  C07K14/235 ,  C12N15/52 ,  C12N1/21 ,  A61K39/02

    CPC分类号： C12R1/01 ,  A61K38/00 ,  A61K2035/11 ,  C07K14/235 ,  C12N15/52

    摘要： The present invention discloses the structure and sequence of aroQ from Bordetella pertussis, which are useful inter alia for the production of the genetically modified attenuated Bordetella strains of the present invention and for detecting and isolating variant aroQ genes and expression products. The present invention also discloses attenuated Bordetella strains of pathogenic origin, and more particularly genetically modified Bordetella strains, which have been attenuated by disruption or inactivation of the aroQ gene. The genetically modified Bordetella strain of the present invention has a reduced capacity to propagate in a mammalian host, but remains viable in the host for a period of time sufficient to induce a protective immune response against the natural pathogenic Bordetella counterpart. The present invention is also directed to the use of such genetically modified Bordetella strains in immunopotentiating compositions for treating and/or preventing inter alia Bordetella infections, and particularly pathogenic infections, caused by Bordetella.

    摘要翻译： 本发明公开了来自百日盛博德氏菌的aroQ的结构和序列，其特别用于生产本发明的遗传修饰的减毒博德特氏菌属菌株，并用于检测和分离变体aroQ基因和表达产物。 本发明还公开了通过aroQ基因的破坏或失活而减毒的致病起源的巴曲特氏菌菌株，更具体地是经遗传修饰的博德特氏菌属菌株。 本发明的遗传修饰的博德氏菌属菌株在哺乳动物宿主中具有降低的繁殖能力，但在宿主中保持足够的时间足以诱导针对天然致病性Bordetella对应物的保护性免疫应答。 本发明还涉及这种遗传修饰的博德特氏菌属菌株在免疫增强组合物中的用途，用于治疗和/或预防博德特氏杆菌感染，特别是由博德氏菌引起的致病性感染。

    Polynucleotide vaccine protective against malaria, methods of protection and vector for delivering polynucleotide vaccines
    17.
    发明授权
    Polynucleotide vaccine protective against malaria, methods of protection and vector for delivering polynucleotide vaccines 失效
    针对疟疾的多核苷酸疫苗，保护方法和用于递送多核苷酸疫苗的载体

    公开(公告)号：US6066623A

    公开(公告)日：2000-05-23

    申请号：US155888

    申请日：1993-11-23

    申请人： Stephen L. Hoffman ,  Richard C. Hedstrom ,  Martha Sedegah

    发明人： Stephen L. Hoffman ,  Richard C. Hedstrom ,  Martha Sedegah

    IPC分类号： A61K39/00 ,  C07K14/11 ,  C07K14/235 ,  C07K14/445 ,  A61K48/00 ,  C12N5/00 ,  C12N15/00

    CPC分类号： C07K14/005 ,  C07K14/235 ,  C07K14/445 ,  A61K2039/53 ,  A61K39/00 ,  C12N2760/16122 ,  Y10S514/895

    摘要： A first embodiment is a specific plasmid vector, pDIP/PyCSP.1, into which nucleotides encoding the targets of specific immune responses are inserted. These targets include, but are not limited to proteins and peptides. These plasmid constructs are incorporated in a composition comprising a suitable and acceptable art recognized pharmaceutical reagent that is benign (non-reactive with) to the plasmid construct. The plasmid construct provides protective immune responses to the disease associated with the selected targets. A second embodiment is a construct having, at a minimum, the nucleotide sequences encoding one or more Plasmodium species proteins in a pharmaceutically acceptable vector. a third embodiment is a method of controlling malaria in mammals comprising injecting a polynucleotide delivery vector into a mammal.

    摘要翻译： 第一个实施方案是特异性质粒载体pDIP / PyCSP.1，其中插入编码特异性免疫应答靶标的核苷酸。 这些靶标包括但不限于蛋白质和肽。 将这些质粒构建体并入包含与质粒构建体良性（非反应性）的合适且可接受的本领域公认的药物试剂的组合物中。 质粒构建体对与所选靶标相关的疾病提供保护性免疫应答。 第二个实施方案是至少在药学上可接受的载体中具有编码一种或多种疟原虫物质蛋白质的核苷酸序列的构建体。 第三个实施方案是控制哺乳动物疟疾的方法，包括将多核苷酸递送载体注射到哺乳动物中。

    Expression of surface layer proteins
    19.
    发明授权
    Expression of surface layer proteins 失效
    表层蛋白的表达

    公开(公告)号：US5874267A

    公开(公告)日：1999-02-23

    申请号：US682517

    申请日：1996-09-17

    申请人： Rolf Y. Deblaere ,  Jan Desomer ,  Patrick Dhaese

    发明人： Rolf Y. Deblaere ,  Jan Desomer ,  Patrick Dhaese

    IPC分类号： C12N15/09 ,  A61K38/00 ,  A61K39/00 ,  C07H21/04 ,  C07K14/235 ,  C07K14/32 ,  C07K14/33 ,  C07K19/00 ,  C12N1/21 ,  C12N15/00 ,  C12N15/12 ,  C12N15/75 ,  C12P21/02 ,  C12R1/07 ,  A61K39/395

    CPC分类号： C12N15/75 ,  C07K14/32 ,  A61K38/00 ,  A61K39/00 ,  C07K2319/00

    摘要： A host cell which is provided with a S-layer comprising a fusion polypeptide consisting essentially of:(a) at least sufficient of a S-layer protein for a S-layer composed thereof to assemble, and(b) a heterologous polypeptide which is fused to either the carboxy terminus of (a) or the amino terminus of (a) and which is thereby presented on the outer surface of the said cell; can be used as a vaccine, for screening for proteins and antigens and as a support for immobilizing an enzyme, peptide or antigen. A process of transforming B. Sphaericus cells comprising electroporation is also provided.

    摘要翻译： PCT No.PCT / EP95 / 00147 Sec。 371日期1996年9月17日 102（e）日期1996年9月17日PCT提交1995年1月13日PCT公布。 WO95 / 19371 PCT出版物 日期1995年7月20日提供了具有S层的宿主细胞，所述S层包含基本上由以下组成的融合多肽：（a）至少足够的用于组合S层的S层蛋白质组装，以及（b） 融合到（a）的羧基末端或（a）的氨基末端的异源多肽，由此呈现在所述细胞的外表面上; 可用作疫苗，用于筛选蛋白质和抗原，并用作固定酶，肽或抗原的支持物。 还提供了包含电穿孔的B.Sphaericus细胞转化过程。

    Manipulation of gene copy number in bordetella
    20.
    发明授权
    Manipulation of gene copy number in bordetella 失效
    在博德特氏菌中操作基因拷贝数

    公开(公告)号：US5849530A

    公开(公告)日：1998-12-15

    申请号：US434846

    申请日：1995-05-04

    申请人： Sheena Loosmore ,  Gavin Zealey ,  Reza Yacoob ,  Michel Klein

    发明人： Sheena Loosmore ,  Gavin Zealey ,  Reza Yacoob ,  Michel Klein

    IPC分类号： A61K39/00 ,  A61K39/10 ,  A61P31/04 ,  C07K14/235 ,  C12N1/21 ,  C12N15/09 ,  C12N15/31 ,  C12P21/02 ,  C12R1/01

    CPC分类号： C07K14/235 ,  A61K39/099 ,  A61K2039/521 ,  A61K39/00

    摘要： A protein expression levels from Bordetella strains, particularly Bordetella pertussis, are altered by genetic modification to a natural Bordetella strain whereby one or more of the natural genes, particularly including the TOX, FHA, CYA and PRN genes, is deleted from the genome of the natural strain and one or more of the natural genes or a genetic mutation thereof, particularly a genetically-detoxified TOX* gene, or a hybrid gene, is inserted into the genome of the natural strain to provide at least two copies of one or more of the natural genes or genetic mutation thereof or hybrid gene, singly or in tandem. The altered genotype Bordetella strain is useful in producing whole-cell or defined component vaccines against Bordetella, particularly whooping cough, which may be employed in combination with other vaccines.

    摘要翻译： 来自博德特氏菌属菌种，特别是百日咳博德特氏菌的蛋白质表达水平，通过对天然博德特氏菌属菌株进行遗传修饰来改变，其中一个或多个天然基因，特别是包括TOX，FHA，CYA和PRN基因，从 将天然菌株和一种或多种天然基因或其遗传突变，特别是遗传上解毒的TOX *基因或杂种基因插入到天然菌株的基因组中，以提供至少两个拷贝的一个或多个 天然基因或其遗传突变或杂交基因，单独或串联。 改变的基因型博德特氏菌属菌株可用于产生针对博德特氏菌的全细胞或定义的组分疫苗，特别是百日咳，其可与其它疫苗组合使用。